Actinium Pharmaceuticals, Inc.: Form 10-Q for the period ended Sep 30, 2022
Filed with the SEC on Nov 14, 2022 and accepted by EDGAR at Nov 14, 2022, 22:01 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2022-07-01 to 2022-09-30 | $45.0k | us-gaap:Revenues |
| Revenue | 9 months2022-01-01 to 2022-09-30 | $1.0m | us-gaap:Revenues |
| Research and development | 3 months2022-07-01 to 2022-09-30 | $6.8m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2022-01-01 to 2022-09-30 | $15.8m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2022-07-01 to 2022-09-30 | −$9.8m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2022-01-01 to 2022-09-30 | −$22.8m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2022-07-01 to 2022-09-30 | −$9.5m | us-gaap:NetIncomeLoss |
| Net income | 9 months2022-01-01 to 2022-09-30 | −$22.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2022-07-01 to 2022-09-30 | −$0.38 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2022-01-01 to 2022-09-30 | −$0.94 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2022-07-01 to 2022-09-30 | −$0.38 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2022-01-01 to 2022-09-30 | −$0.94 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2022-07-01 to 2022-09-30 | 25,164,599 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2022-01-01 to 2022-09-30 | 23,691,218 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2022-01-01 to 2022-09-30 | $16.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2022-01-01 to 2022-09-30 | $350.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2022-09-30 | $111.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-09-30 | $113.4m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-09-30 | $116.8m | us-gaap:Assets |
| Current liabilities | At period end2022-09-30 | $8.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-09-30 | $45.6m | us-gaap:Liabilities |
| Shareholders' equity | At period end2022-09-30 | $71.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001213900-22-072371. Last ingested by Listed: Oct 24, 2026, 15:12 ET. Listed shows no prices and gives no investment advice.